Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Cancer Imaging and Image-directed Interventions
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1432758
This article is part of the Research Topic Diagnosis, Treatment and Prognosis of Neuroendocrine Neoplasms with a focus on peptide receptor radionuclide therapy (PRRT) View all articles

Resolution of VIPoma-related Symptoms with Peptide Receptor Radionuclide Therapy

Provisionally accepted
Turgut Bora Cengiz Turgut Bora Cengiz *Raksha Kulkarni Raksha Kulkarni Rahman Akinlusi Rahman Akinlusi Virginia Corbett Virginia Corbett Nasrin V Ghesani Nasrin V Ghesani Edward Wolin Edward Wolin Munir Ghesani Munir Ghesani
  • Mount Sinai Hospital, New York, United States

The final, formatted version of the article will be published soon.

    Peptide receptor radionuclide therapy (PRRT) is used for the management of neuroendocrine tumors (NET) not responsive to somatostatin analogs. In this case series, we reported two patients with pancreatic vasoactive intestinal peptide (VIP) secreting NET not responsive to any other therapies, who achieved symptomatic control and a significant decrease in serum VIP level with PRRT during their hospital stay.Two patients with VIPomas were admitted to the hospital with multiple prior hospital admissions after going through multiple lines of therapy. The first patient is a 47-year-old female with a grade 2 pancreatic NET-secreting VIP. She was treated with somatostatin analogs and chemotherapy; however, she experienced recurrent symptoms and complications leading to 2 hospital admissions, one of which included an ICU admission. The patient was treated with Lutetium-177 DOTATATE while in the hospital, which led to the resolution of the symptoms and a marked decline in serum VIP level and was able to be discharged from the hospital after 147 days of admission (16 days after PRRT). The second patient was a 27-year-old male who was diagnosed with a well-differentiated grade 3 pancreatic VIPoma. He also suffered from severe diarrhea, not responsive to any form of therapy including liver embolizations. He was also treated with PRRT during his admission, which led to immediate resolution of his symptoms and a decrease in tumor markers.In conclusion, 177 Lutetium-DOTATATE is an effective treatment for highly symptomatic VIPoma. Inpatient administration of PRRT can rapidly decrease the diarrhea and fluid and electrolyte complications of VIP secretion and may shorten hospital stay.

    Keywords: PRRT, Vipoma, inpatient PRRT, Neuroendochrine tumor, pancreatic net, 68Ga DOTATATE PET CT, theranostics

    Received: 14 May 2024; Accepted: 21 Oct 2024.

    Copyright: © 2024 Cengiz, Kulkarni, Akinlusi, Corbett, Ghesani, Wolin and Ghesani. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Turgut Bora Cengiz, Mount Sinai Hospital, New York, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.